TNF and inflammatory bowel disease: In patients with IBD, biologic treatments antagonizing immunomodulating factors that either activate T cells (interleukin [IL]-12/23, ustekinumab, etc.)or are expressed by T cells (α4β7 integrin; velodizumab, tumor necrosis factor [TNF]; infliximab, etc.)are effective in the majority of the patients.10